WO2022269451 - BISPECIFIC ANTIBODIES FOR USE IN TREATMENT OF HIDRADENITIS SUPPURATIVA
National phase entry:
Publication Number
WO/2022/269451
Publication Date
29.12.2022
International Application No.
PCT/IB2022/055690
International Filing Date
20.06.2022
Title **
[English]
BISPECIFIC ANTIBODIES FOR USE IN TREATMENT OF HIDRADENITIS SUPPURATIVA
[French]
ANTICORPS BISPÉCIFIQUES DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE L'HIDROSADÉNITE SUPPURÉE
Applicants **
NOVARTIS AG
Inventors
BECK, Sabine
KIFFE, Michael
KOVARIK, Jiri
LOESCHE, Christian
RODRIGUES, Margarida
STEIN, Richard
TANG, Yu
WALDRON-LYNCH, Frank
Priority Data
63/213,686
22.06.2021
US
63/223,479
19.07.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3016 | |
| EPO | Filing, Examination, Granting | 15852 | |
| Japan | Filing, Examination, Granting | 2485 | |
| South Korea | Filing, Examination, Granting | 2701 | |
| USA | Filing, Examination, Granting | 6190 |
Total:
30,244
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The invention relates to bivalent bispecific monoclonal antibodies (bbmAb) or variants thereof for use in the treatment or for use in alleviating the symptoms of hidradenitis suppurativa in a subject.[French]
L'invention concerne des anticorps monoclonaux bispécifiques bivalents (bbmAb) ou des variants de ceux-ci destinés à être utilisés dans le traitement ou pour le soulagement des symptômes de l'hidrosadénite suppurée chez un sujet.